Our systematic review and meta-analysis evaluated the efficacy and safety of VMAT-2 inhibitors (tetrabenazine, deutetrabenazine, valbenazine) and dopamine stabilizers (pridopidine) in treating chorea in Huntington’s disease. Here, SLC18A2 is linked to choreatic disease.